Purpose To address the question of whether users of herbal products (HPs) are exposed to harmful contaminants, we evaluated six HPs mostly patronized in Kumasi for heavy metal contamination and assessed the health risk associated with their use. This study is one of the first safety evaluation studies on finished multiherbal products in the region. Method Three antimalarial, two antidiabetic and one antihypertensive HPs were selected after a mini-survey and coded randomly as HP A-F. The HPs were acid digested for quantitative analysis of heavy metals using Inductively Coupled Plasma Mass Spectrometer. Hg quantification was carried out using cold vapour atomic absorption spectroscopy. Results The cancer risk estimation values for the carcinogenic metals ranged between 1.54 × 10 −9 to 3.73 × 10 −4 and were all within acceptable limits. The non-cancer health risk evaluation revealed that, some of the products pose health risk to consumers. The estimated daily intake (EDI) for As in HPF was 2.48 × 10 −4 mg/kg/day compared to the reference limit of 1.67 × 10 −4 mg/kg/ day. HPF also had high hazard index (HI) of 5.70 (HI >1) in children as compared to 1.68 (HI >1) in adults showing a 3.4 folds increase in the health risk among the former. Conclusion The six polyherbal products exhibited carcinogenic risk within acceptable limits. Although, the non-carcinogenic risk assessment of products HPA to HPE suggests safety, this can only be ascertained after further characterization of their health risks in detailed chronic toxicity studies. The high HI for product HPF suggests health risk for consumers of this product.

No abstract

Purpose: Safety data on commonly used herbal medicinal (HM) products (HMPs) and marketed in Ghana are scarce. We assessed the sub-chronic toxicity of three most-patronised commercial antimalarial HMPs in Kumasi, Ghana. Method: Top three HMPs (designated as herbal products ‘A’ (HPA), ‘B’ (HPB) and ‘C’ (HPC)) were selected after a mini-survey and sub-chronic toxicity evaluation conducted in accordance with Organisation for Economic Co-operation and Development (OECD) 407 guidelines. Control rats received clean water while test groups received daily adult human dose (DAHD), 5× DAHD or 10× DAHD of either HPA, HPB or HPC for 30 days. Rats were killed on day 31 to obtain biochemical, haematology and histology samples for analysis. Data were analysed by one-way analysis of variance (ANOVA) and post hoc Tukey’s test. Results: The three HMPs produced alterations in liver morphology predominantly characterised by prominent foci of fatty change with scattered hepatocytes containing intracytoplasmic fat globules and congested central veins and sinusoids. The lungs showed alveolar with evidence of inflammation and foci of epithelial sloughing. Alveolar spaces were also obscured by debris and inflammatory cells. HPA and HPC produced scattered intensely congested heart vessels while HPB(10) produced haemorrhage and amorphous exudates within the heart. All HMPs produced neither treatment-related deaths nor significant change in haematological and biochemical parameters, except for HPA and HPB which decreased (P<0.05) aspartate aminotransferase (AST) and HPB, which elevated (P<0.05) fasting blood glucose (FBG). Conclusion: Data from the present study suggest the potential of the herbal products (HPs), HPA, HPB and HPC, to cause major organ-system dysfunction or damage. We advise cautious use of these products and recommend further safety evaluation in chronic toxicity models.

Introduction: Acute respiratory infections are continuously emerging. Discovered in Wuhan city, China in 2019, COV-SARS-2 and most viral respiratory diseases presently do not have a definitive cure. This paper aims to evaluate the therapeutic effectiveness of ginseng for the prevention and control of acute respiratory illness including SARS-COV-2 in the adult population. Method: We performed a systematic literature review using databases PubMed, Medline, Scopus, Google Scholar, Web of Science, and Cochrane library from 1st through the 27th of April 2020. All related articles that reported the use of Ginseng in COVID-19 patients were included in this analysis. The screening was done by 2-independent researchers. The meta-analysis was performed using a comprehensive meta-analysis package. Result: 596 articles were retrieved for the time frame. After screening, 5 articles with RCTs outcomes relevant to the review were selected. Ginseng was found to be effective in the reduction of risk by 38 % and 3-days shorter duration of acute respiratory illness (ARI) in all trials than placebo. Conclusion: As the world continues to race to find a cure, it is important to consider the use of ginseng which has been proven over the years to be effective in the treatment of acute respiratory illnesses. Further studies should however be conducted to determine the right dosage to improve efficacy and prevent adverse events.